Ionis bags a $75M milestone from Bayer; Inventiva garners $51M from IPO

B. Lynne Parshall, Ionis

• Ionis Pharmaceuticals $IONS is picking up a $75 million milestone payment from Bayer related to IONIS-FXIRx. Ionis plans to start a Phase IIb study with IONIS-FXIRX in patients with end-stage renal disease who are on hemodialysis. “We recently completed a Phase II study in patients with end-stage renal disease on hemodialysis, in which IONIS-FXIRx demonstrated robust reductions in Factor XI activity and no treatment-related major bleeding, ” stated B. Lynne Parshall, COO at Ionis Pharmaceuticals.

• Inventiva has steered onto the Paris market, reaping $51 million from its IPO as it preps for a mid-stage NASH study. The biotech prices its shares at the low end of the range.

• Ipsen is adding 100 workers from Merrimack under its recent cancer drug deal, according to the Boston Business Journal.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->